|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, only the HS tumor had a KRAS mutation while the lymph node involved by FL harbored a TNFAIP3 mutation and both tumors also showed distinct chromosomal alterations.
|
31807922 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining liver protection with tumor inhibition is a unique advantage of A20, which has the potential to be a novel treatment for promoting liver regeneration following liver resection in patients with HCC with liver cirrhosis.
|
31134613 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, TNFAIP3 knockout not only inhibited the AP20187-induced proliferation and tumor growth of DCIS-iFGFR1 cells, but also further reduced baseline proliferation and tumor growth of DCIS-iFGFR1 cells without AP20187 treatment.
|
30111373 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy.
|
29233925 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the regulatory effects of miR-19a on TNFAIP3 and NF-κB signaling were confirmed using tumor samples from patients with colon cancer.
|
27991929 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Somatic mutations of B-cell function genes were further screened on 275 (71 non-CR and 204 CR) cases with available tumor samples by targeted sequencing, including genes involved in B-cell receptors (BCRs) pathway (CARD11, LYN, CD79A, and CD79B), Toll-like receptors (TLRs) pathway (MYD88), and tumor necrotic factor receptor (TNFR) pathway (TRAF2 and TNFAIP3).
|
28153771 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequent analyses of clinical patient samples confirmed a correlation between tumor TNFAIP3 expression levels and overall survival in patients with ACC.
|
26768118 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, other KMT2D target genes include frequently mutated tumor suppressor genes such as TNFAIP3, SOCS3 and TNFRSF14.
|
26366710 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor A20 [also known as TNFAIP3 (tumor necrosis factor-α-induced protein 3)] inhibits an upstream activator of NF-κB and is often mutated in lymphomas.
|
23901138 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental results indicate that TNFAIP3 may act as a tumor suppressor in CRC.
|
22843550 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we show that A20 is also a putative tumor suppressor in the T-cell malignancy-SS.
|
21625233 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that miR-29c may play an important role as a tumor suppressive microRNA in the development and progression of HBV-related HCC by targeting TNFAIP3.
|
21763284 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice.
|
21088135 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
|
19380639 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, homozygous deletions of the chromosomal band 6q23, involving the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) gene, a negative regulator of NF-kappaB, were described in ocular adnexal MZL, suggesting a role for A20 as a tumor suppressor in this disease.
|
19258598 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
|
19608751 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNFAIP3 is an inhibitor of NF-kB signaling so that loss of this gene may play an important role in lymphomagenesis and suggests that TNFAIP3 may act as a tumor suppressor gene in ocular adnexal marginal zone B cell lymphoma.
|
17886247 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, BCR/ABL1 was found to activate several genes involved in negative feedback regulation (CISH, SOCS2, SOCS3, PIM1, DUSP6, and TNFAIP3), which may act to indirectly suppress the tumor promoting effects exerted by BCR/ABL1.
|
18181176 |
2008 |